skip to main content
Visitante
Meu Espaço
Minha Conta
Sair
Identificação
This feature requires javascript
Tags
Revistas Eletrônicas (eJournals)
Livros Eletrônicos (eBooks)
Bases de Dados
Bibliotecas USP
Ajuda
Ajuda
Idioma:
Inglês
Espanhol
Português
This feature required javascript
This feature requires javascript
Primo Search
Busca Geral
Busca Geral
Acervo Físico
Acervo Físico
Produção Intelectual da USP
Produção USP
Search For:
Clear Search Box
Search in:
Busca Geral
Or hit Enter to replace search target
Or select another collection:
Search in:
Busca Geral
Busca Avançada
Busca por Índices
This feature requires javascript
Tipo de recurso
criteria input
qualquer lugar do registro
no título
como autor
no assunto
Data de publicação
lsr01
lsr02
lsr03
lsr04
Orientador
Show Results with:
no título
Show Results with:
qualquer lugar do registro
no título
como autor
no assunto
Data de publicação
lsr01
lsr02
lsr03
lsr04
Orientador
Mostra resultados com:
criteria input
que contêm minhas palavras de busca
com a frase exata
começa com
Mostra resultados com:
Índice
criteria input
E
OU
NÃO
This feature requires javascript
Gastrointestinal stromal tumor (GIST): advances in 2013
Daum, Ondřej ; Sedivcová, Monika
Ceskoslovenské patologie, 2014-04, Vol.50 (2), p.76-80
[Periódico revisado por pares]
Czech Republic
Texto completo disponível
Citações
Citado por
Exibir Online
Detalhes
Resenhas & Tags
Mais Opções
Nº de Citações
This feature requires javascript
Enviar para
Adicionar ao Meu Espaço
Remover do Meu Espaço
E-mail (máximo 30 registros por vez)
Imprimir
Link permanente
Referência
EasyBib
EndNote
RefWorks
del.icio.us
Exportar RIS
Exportar BibTeX
This feature requires javascript
Título:
Gastrointestinal stromal tumor (GIST): advances in 2013
Autor:
Daum, Ondřej
;
Sedivcová, Monika
Assuntos:
Adult
;
Child
;
Chondroma - classification
;
Chondroma - drug therapy
;
Chondroma - genetics
;
Chondroma - pathology
;
Gastrointestinal Stromal Tumors - classification
;
Gastrointestinal Stromal Tumors - drug therapy
;
Gastrointestinal Stromal Tumors - genetics
;
Gastrointestinal Stromal Tumors - pathology
;
Humans
;
Immunohistochemistry
;
Leiomyosarcoma - classification
;
Leiomyosarcoma - drug therapy
;
Leiomyosarcoma - genetics
;
Leiomyosarcoma - pathology
;
Lung Neoplasms - classification
;
Lung Neoplasms - drug therapy
;
Lung Neoplasms - genetics
;
Lung Neoplasms - pathology
;
Mutation
;
Paraganglioma - classification
;
Paraganglioma - drug therapy
;
Paraganglioma - genetics
;
Paraganglioma - pathology
;
Paraganglioma, Extra-Adrenal - classification
;
Paraganglioma, Extra-Adrenal - drug therapy
;
Paraganglioma, Extra-Adrenal - genetics
;
Paraganglioma, Extra-Adrenal - pathology
;
Pharmacogenetics
;
Proto-Oncogene Proteins c-kit - genetics
;
Receptor, Platelet-Derived Growth Factor alpha - genetics
;
Risk Assessment
;
Stomach Neoplasms - classification
;
Stomach Neoplasms - drug therapy
;
Stomach Neoplasms - genetics
;
Stomach Neoplasms - pathology
;
Succinate Dehydrogenase
É parte de:
Ceskoslovenské patologie, 2014-04, Vol.50 (2), p.76-80
Notas:
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição:
Gastrointestinal stromal tumors (GIST) are currently regarded as a heterogenous group of tumors sharing common histological appearance, KIT immunopositivity and supposed origin from tissue progenitor cells capable of differentiation into the phenotype of Cajal interstitial cells. GISTs can be divided according to immunoexpression of the beta subunit of mitochondrial enzyme succinate dehydrogenase (SDHB) to SDHB-positive (encompassing KIT, PDGFRA and NF1 mutated GISTs), and SDHB-deficient GISTs (including Carney-Stratakis syndrome, Carney triad, sporadic pediatric GISTs, and a small subset of sporadic adult GISTs). The individual molecular subtypes differ in biological behavior and in their response to systemic targeted therapy, which is indicated in metastatic GISTs or in tumors with high risk of recurrence. Although several risk-stratification classifications have been developed, strictly defined criteria to identify patients at risk are still lacking. Pharmacogenomics have been successful in designing drugs to overcome not only the primary resistance of GISTs to the action of imatinib (e.g. GISTs with a substitution of Asp842Val in exon 18 PDGFRA or SDHB-deficient GISTs), but also the secondary resistance caused by secondary mutation of a gene encoding either the receptor tyrosine kinase or other molecules involved in the respective signalling cascade. Future directions concentrate on rational molecular targeting for systemic therapy based on complex genetic investigation of the tumor. Peripheral blood is planned to be used as a source of information for genetic events responsible for the secondary resistance of metastatic tumors.
Editor:
Czech Republic
Idioma:
Tcheco
Links
View this record in MEDLINE/PubMed
This feature requires javascript
This feature requires javascript
Voltar para lista de resultados
This feature requires javascript
This feature requires javascript
Buscando em bases de dados remotas. Favor aguardar.
Buscando por
em
scope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
Mostrar o que foi encontrado até o momento
This feature requires javascript
This feature requires javascript